OBJECTIVE: The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab. CONCLUSION: Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
OBJECTIVE: The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab. CONCLUSION: Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
Authors: Richard G Abramson; Vandana G Abramson; Emily Chan; Leora Horn; Vicki L Keedy; William Pao; Jeffrey A Sosman Journal: AJR Am J Roentgenol Date: 2013-03 Impact factor: 3.959
Authors: Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino Journal: Cancer Immunol Res Date: 2015-06-22 Impact factor: 11.151
Authors: Kyung Won Kim; Nikhil H Ramaiya; Katherine M Krajewski; Jyothi P Jagannathan; Sree Harsha Tirumani; Amitabh Srivastava; Nageatte Ibrahim Journal: Invest New Drugs Date: 2013-02-14 Impact factor: 3.850